JP3799151B2 - Topical skin preparation - Google Patents
Topical skin preparation Download PDFInfo
- Publication number
- JP3799151B2 JP3799151B2 JP36458397A JP36458397A JP3799151B2 JP 3799151 B2 JP3799151 B2 JP 3799151B2 JP 36458397 A JP36458397 A JP 36458397A JP 36458397 A JP36458397 A JP 36458397A JP 3799151 B2 JP3799151 B2 JP 3799151B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- skin
- pine
- make
- butylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims description 15
- 230000000699 topical effect Effects 0.000 title description 2
- 239000000284 extract Substances 0.000 claims description 30
- 241000018646 Pinus brutia Species 0.000 claims description 16
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 12
- 235000011613 Pinus brutia Nutrition 0.000 claims description 12
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 30
- 238000004519 manufacturing process Methods 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 210000003491 skin Anatomy 0.000 description 21
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 229940058015 1,3-butylene glycol Drugs 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 235000019437 butane-1,3-diol Nutrition 0.000 description 15
- 239000012071 phase Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 229960001340 histamine Drugs 0.000 description 10
- -1 pH adjusters Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000008213 purified water Substances 0.000 description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 241000721662 Juniperus Species 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 239000002304 perfume Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000006071 cream Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000003788 bath preparation Substances 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241001149110 Limonium wrightii Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 229920002055 compound 48/80 Polymers 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Description
【0001】
【産業上の利用分野】
本発明は、磯松の抽出物を含有することを特徴とする皮膚外用剤に関する。
【0002】
【従来の技術】
磯松は南西諸島では茎や葉を飲用して関節炎の治療に用いたり、鑑賞用として栽培されているが、皮膚外用剤に利用された例はない。
一方、肌荒れの一因として紫外線などによる皮膚炎症があり、その炎症を沈め、肌荒れを改善する皮膚外用剤が望まれている。その治療法の一つとして、炎症時に生じる起炎物質であるヒスタミンの遊離を抑制する方法がある。しかしながら、従来のヒスタミン遊離抑制作用をもつ皮膚外用剤は、ステロイド剤などの化学合成で得られた物質を含有するものがほとんどであり、副作用の危険性もあるため、安全性が高く、効果の優れた天然物由来の皮膚外用剤が望まれている。
【0003】
【発明が解決しようとする課題】
そこで、天然物として磯松の抽出物について、皮膚外用剤への応用を検討したところ、安全性が高く、優れた抗炎症作用(ヒスタミン遊離抑制作用)および美肌作用を示し、かつ、製剤化も可能なことから本発明を完成した。
【0004】
【課題を解決するための手段】
本発明は、磯松の抽出物を含有することを特徴とする皮膚外用剤である。
本発明でいう磯松(Limonium wrightii O. Kuntze)とは、イソマツ科イソマツ属に属する双子葉植物の小低木状の多年草で、伊豆七島、屋久島以南から台湾、小笠原に分布する。また、この磯松は台湾では海芙蓉とも呼ばれている。
【0005】
本発明で使用する磯松の抽出物とは、磯松の葉、茎、花、実、根の植物体の一部または全草から抽出して得られるものである。好ましくは、葉もしくは茎の一方、もしくは両方の混合物から抽出して得られるものがよい。その調製方法は特に限定されず、例えば、加熱抽出したものであっても良いし、常温抽出したものであっても良い。また、抽出する溶媒としては、例えば、水、低級1価アルコ−ル類(メタノ−ル、エタノ−ル、1-プロパノール、2-プロパノール、1-ブタノール、2-ブタノール等)、液状多価アルコール(1,3-ブチレングリコール、プロピレングリコール等)、エステル類(酢酸エチル、ミリスチン酸イソプロピル等)、炭化水素類(ベンゼン、 ヘキサン、 ペンタン、流動パラフィン等)、ケトン類(アセトン、メチルエチルケトン等)、エーテル類(エチルエーテル、テトラヒドロフラン、プロピルエーテル等)、アセトニトリル等が挙げられる。これらの溶媒は単独で用いても2種以上を混合して用いても良い。好ましくは、水もしくは水溶性溶媒(水と任意の割合で混合可能な溶媒、例えば、エタノール、1,3-ブチレングリコール、プロピレングリコール等)のうち1種または2種以上の溶媒を用いるのがよい。
【0006】
また、磯松の抽出物は、抽出された溶液のまま用いても良く、必要に応じて、濃縮、希釈、濾過等の処理をして用いてもよい。
【0007】
本発明の皮膚外用剤には磯松の抽出物の効果を損なわない範囲内で、通常の皮膚外用剤に用いられる成分である油脂類、ロウ類、炭化水素類、脂肪酸類、アルコール類、エステル類、界面活性剤、金属石鹸、pH調整剤、防腐剤、香料、保湿剤、粉体、紫外線吸収剤、増粘剤、色素、酸化防止剤、美容成分、キレート剤等の成分を配合することができる。
【0008】
本発明の皮膚外用剤は医薬品、医薬部外品、化粧品のいずれにも用いることができ、その剤型としては、例えば、化粧水、クリ−ム、乳液、ゲル剤、エアゾール剤、軟膏、パップ剤、ペースト剤、プラスター剤、エッセンス、パック、洗浄剤、浴用剤、ファンデ−ション、打粉、口紅等の皮膚に適用されるものが挙げられる。
【0009】
本発明に用いる磯松の抽出物の配合量は、本発明皮膚外用剤の全量中、乾固物に換算して0.0001重量%以上、好ましくは0.001〜10重量%の配合が良い。0.001重量%未満では十分な効果は望めない。10重量%を越えて配合した場合、効果の増強はなく不経済である。また、添加の方法については、予め加えておいても、製造途中で添加しても良く、作業性を考えて適宜選択すれば良い。
【0010】
【実施例】
次に本発明を実施例をあげて詳細に説明するが、本発明はこれに限定されるものではない。なお、実施例に示す配合量の部とは重量部を、%とは重量%を示す。
【0011】
製造例1 磯松熱水抽出物
磯松の茎と葉の混合物50gに1000mlの水を加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し乾固して、磯松熱水抽出物10.5gを得た。
【0012】
製造例2 磯松エタノール抽出物
磯松の葉 50gに1000mlのエタノールを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮し乾固して、磯松エタノール抽出物4.0gを得た。
【0013】
製造例3 磯松1,3-ブチレングリコール抽出物
磯松の全草の乾燥物50gに、1,3-ブチレングリコール1000gを加え、常温で10日間抽出した後、濾過し、磯松1,3-ブチレングリコール抽出物800gを得た。
【0014】
実施例1 化粧水
処方 配合量
1. 磯松熱水抽出物(製造例1) 0.1部
2. 1,3-ブチレングリコール 8.0
3. グリセリン 2.0
4. キサンタンガム 0.02
5. クエン酸 0.01
6. クエン酸ナトリウム 0.1
7. エタノール 5.0
8. パラオキシ安息香酸メチル 0.1
9. ポリオキシエチレン硬化ヒマシ油(40E.O.) 0.1
10. 香料 適量
11. 精製水にて全量を100とする
[製造方法]成分1〜6、11と、成分7〜10をそれぞれ均一に溶解し、両者を混合し濾過して製品とする。
【0015】
比較例1 従来の化粧水
実施例1において、磯松熱水抽出物を精製水に置き換えたものを従来の化粧水とした。
【0016】
実施例2 クリーム
処方 配合量
1. 磯松エタノール抽出物(製造例2) 0.05部
2. スクワラン 5.5
3. オリーブ油 3.0
4. ステアリン酸 2.0
5. ミツロウ 2.0
6. ミリスチン酸オクチルドデシル 3.5
7. ポリオキシエチレンセチルエーテル(20E.O.) 3.0
8. ベヘニルアルコール 1.5
9. モノステアリン酸グリセリン 2.5
10. 1,3-ブチレングリコール 8.5
11. パラオキシ安息香酸メチル 0.2
12. パラオキシ安息香酸エチル 0.05
13. 香料 0.1
14. 精製水にて全量を100とする
[製造方法]成分2〜9を加熱溶解して混合し、70℃に保ち油相とする。成分 1、10〜12、14を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分13を加え、更に30℃まで冷却して製品とする。
【0017】
実施例3 乳液
処方 配合量
1. 磯松1,3-ブチレングリコール抽出物(製造例3) 1.0部
2. スクワラン 5.0
3. オリーブ油 5.0
4. ホホバ油 5.0
5. セタノール 1.5
6. モノステアリン酸グリセリン 2.0
7. ポリオキシエチレンセチルエーテル(20E.O.) 3.0
8. ポリオキシエチレンソルビタンモノオレエート(20E.O.) 2.0
9. プロピレングリコール 1.0
10. グリセリン 2.0
11. パラオキシ安息香酸メチル 0.2
12. 香料 0.1
13. 精製水にて全量を100とする
[製造方法]成分2〜8を加熱溶解して混合し、70℃に保ち油相とする。成分 1、 9〜11、13を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分12を加え、更に30℃まで冷却して製品とする。
【0018】
比較例2 従来の乳液
実施例3において、磯松1,3-ブチレングリコール抽出物を1,3-ブチレングリコールに置き換えたものを従来の乳液とした。
【0019】
実施例4 ゲル剤
処方 配合量
1. 磯松1,3-ブチレングリコール抽出物(製造例3) 5.0部
2. エタノール 5.0
3. パラオキシ安息香酸メチル 0.1
4. ポリオキシエチレン硬化ヒマシ油(60E.O.) 0.1
5. 香料 適量
6. 1,3-ブチレングリコール 5.0
7. グリセリン 5.0
8. キサンタンガム 0.1
9. カルボキシビニルポリマー 0.2
10. 水酸化カリウム 0.2
11. 精製水にて全量を100とする
[製造方法]成分2〜5と、成分1、6〜11をそれぞれ均一に溶解し、両者を混合し濾過して製品とする。
【0020】
実施例5 軟膏
処方 配合量
1. 磯松熱水抽出物(製造例1) 1.0部
2. ポリオキシエチレンセチルエーテル(30E.O.) 2.0
3. モノステアリン酸グリセリン 10.0
4. 流動パラフィン 5.0
5. セタノール 6.0
6. パラオキシ安息香酸メチル 0.1
7. プロピレングリコール 10.0
8. 精製水にて全量を100とする
[製造方法]成分2〜5を加熱溶解して混合し、70℃に保ち油相とする。成分 1、 6〜8に加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら30℃まで冷却して製品とする。
【0021】
実施例6 パック
処方 配合量
1. 磯松熱水抽出物(製造例1) 0.5部
2. ポリビニルアルコール 12.0
3. エタノール 5.0
4. 1,3-ブチレングリコール 8.0
5. パラオキシ安息香酸メチル 0.2
6. ポリオキシエチレン硬化ヒマシ油(20E.O.) 0.5
7. クエン酸 0.1
8. クエン酸ナトリウム 0.3
9. 香料 適量
10. 精製水にて全量を100とする
[製造方法]成分1〜10を均一に溶解し製品とする。
【0022】
実施例7 ファンデーション
処方 配合量
1. 磯松1,3-ブチレングリコール抽出物(製造例3) 1.0部
2. ステアリン酸 2.4
3. ポリオキシエチレンソルビタンモノステアレート(20E.O.) 1.0
4. ポリオキシエチレンセチルエーテル(20E.O.) 2.0
5. セタノール 1.0
6. 液状ラノリン 2.0
7. 流動パラフィン 3.0
8. ミリスチン酸イソプロピル 6.5
9. パラオキシ安息香酸ブチル 0.1
10. カルボキシメチルセルロースナトリウム 0.1
11. ベントナイト 0.5
12. プロピレングリコール 4.0
13. トリエタノールアミン 1.1
14. パラオキシ安息香酸メチル 0.2
15. 二酸化チタン 8.0
16. タルク 4.0
17. ベンガラ 5.0
18. 香料 適量
19. 精製水にて全量を100とする
[製造方法]成分19の一部に成分10をよく膨潤させ、残りの成分19に成分13を溶解させたものを加え、続いて、成分1、11〜14を加えて均一に混合し水相とする。成分2〜9を加熱溶解し、80℃に保ち油相とする。成分15〜17を粉砕機で粉砕し、水相に加え、ホモミキサーで攪拌し75℃に保つ。この水相に油相をかき混ぜながら加え、冷却し、45℃で成分18を加え、かき混ぜながら30℃まで冷却して製品とする。
【0023】
実施例8 ヘアークリーム
処方 配合量
1. ステアリン酸 2.0部
2. ステアリルアルコール 2.0
3. 流動パラフィン 8.0
4. グリセリンモノステアレート 2.3
5. ソルビタンモノオレート 2.5
6. ポリオキシエチレンソルビタンモノオレート(10E.O.) 0.8
7. 磯松1,3-ブチレングリコール抽出物(製造例3) 0.2
8. グリセリン 6.0
9. パラオキシ安息香酸メチル 0.1
10. 香料 適量
11. 精製水にて全量を100とする
[製造方法]成分1〜6を加熱溶解して混合し、70℃に保ち油相とする。成分7〜 10を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分10を加え、更に30℃まで冷却して製品とする。
【0024】
実施例9 浴用剤
処方 配合量
1. 炭酸水素ナトリウム 50.0部
2. 磯松熱水抽出物(製造例1) 0.5
3. 黄色202号 適量
4. 香料 適量
5. 硫酸ナトリウムにて全量を100とする
[製造方法]成分1〜5を均一に混合し製品とする。
【0025】
【発明の効果】
本発明の磯松の抽出物は優れたヒスタミン遊離抑制作用(抗炎症作用)を有し、また、磯松の抽出物を含有することを特徴とする皮膚外用剤は優れた美肌作用を示した。
次に、本発明の効果を詳細に説明するため、実験例を挙げる。
【0026】
実験例1 ヒスタミン遊離を抑制する作用(抗炎症作用)
雄性Spraque-Dawley系ラットの腹腔内から採取した肥満細胞を用いてヒスタミン遊離抑制作用を測定した。すなわち、1μg/mlのコンパウンド48/80による肥満細胞からのヒスタミン遊離を抑制する作用を遊離抑制率として求めた。肥満細胞はSullivanらの方法(J. Immunology,114(5),1473,1975)で採取し、ヒスタミンの定量はMayらの方法(J. Allergy,46,12-20,1970)で行った。実験の結果を表1に示した。その結果、磯松の抽出物は優れたヒスタミン遊離抑制作用を示した。なお、試料は製造例1および2の抽出物の凍結乾燥品、製造例3の抽出物の蒸発残留物を用いた。
【0027】
【表1】
【0028】
実験例2 美肌作用
実施例1の化粧水、実施例3の乳液、比較例1の従来の化粧水および比較例2の従来の乳液を用いて、肌荒れに悩む女性15人(21〜46才)を対象に1ヶ月間の使用試験を行った。使用後、肌荒れの改善効果をアンケートにより判定した。その結果を表2に示した。その結果、磯松の抽出物を含有することを特徴とする皮膚外用剤は優れた美肌作用を示した。
【0029】
【表2】
【0030】
実施例2のクリーム、実施例4のゲル剤、実施例5の軟膏、実施例6のパック、実施例7のファンデーション、実施例8のヘアークリームおよび実施例9の浴用剤についても同様に使用試験を行ったところ、優れた美肌作用を示した。
以上示したように、本発明の磯松の抽出物は優れたヒスタミンの遊離を抑制する作用を有し、さらに、その抽出物を含有することを特徴とする皮膚外用剤は優れた美肌作用を示した。[0001]
[Industrial application fields]
The present invention relates to a skin external preparation characterized by containing an extract of pine cones.
[0002]
[Prior art]
In the Nansei Islands, pine pine is used for the treatment of arthritis by drinking stems and leaves, but it has been cultivated for viewing purposes.
On the other hand, there is skin inflammation caused by ultraviolet rays or the like as a cause of rough skin, and an external preparation for skin that subsides the inflammation and improves rough skin is desired. As one of the treatment methods, there is a method for suppressing the release of histamine, which is a inflammatory substance that occurs during inflammation. However, most conventional skin external preparations having an inhibitory action on histamine release contain substances obtained by chemical synthesis such as steroids, and there is a risk of side effects. An excellent natural product-derived skin external preparation is desired.
[0003]
[Problems to be solved by the invention]
Therefore, as a natural product, we examined the application of pine pine extract to the topical skin preparation. As a result, it is highly safe, exhibits excellent anti-inflammatory action (histamine release inhibitory action) and skin beautification, and can also be formulated. Thus, the present invention has been completed.
[0004]
[Means for Solving the Problems]
The present invention is a skin external preparation characterized by containing an extract of pine cones.
Limonium wrightii O. Kuntze in the present invention is a dicotyledonous small shrub perennial plant belonging to the genus Isomatsuaceae, and is distributed from Izu-Nanashima, south of Yakushima to Taiwan and Ogasawara. In addition, this pine is also called Haidian in Taiwan.
[0005]
The extract of juniper pine used in the present invention is obtained by extracting from a part of a plant of pine pine leaves, stems, flowers, berries, roots or whole plants. Preferably, it is obtained by extraction from one or both of leaves and stems. The preparation method is not particularly limited, and for example, it may be extracted by heating or may be extracted at room temperature. Examples of the solvent to be extracted include water, lower monohydric alcohols (methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, etc.), liquid polyhydric alcohols. (1,3-butylene glycol, propylene glycol, etc.), esters (ethyl acetate, isopropyl myristate, etc.), hydrocarbons (benzene, hexane, pentane, liquid paraffin, etc.), ketones (acetone, methyl ethyl ketone, etc.), ether (Ethyl ether, tetrahydrofuran, propyl ether, etc.), acetonitrile and the like. These solvents may be used alone or in combination of two or more. Preferably, one or two or more of water or a water-soluble solvent (a solvent that can be mixed with water in an arbitrary ratio, such as ethanol, 1,3-butylene glycol, propylene glycol, etc.) may be used. .
[0006]
Moreover, the extract of Juniper may be used as it is, or may be used after being subjected to treatments such as concentration, dilution, and filtration as necessary.
[0007]
Oils and waxes, waxes, hydrocarbons, fatty acids, alcohols, esters, which are components used in normal skin external preparations, as long as they do not impair the effect of the extract of pine cones , Surfactants, metal soaps, pH adjusters, preservatives, fragrances, moisturizers, powders, UV absorbers, thickeners, dyes, antioxidants, cosmetic ingredients, chelating agents, etc. it can.
[0008]
The skin external preparation of the present invention can be used for any of pharmaceuticals, quasi drugs, and cosmetics. Examples of the dosage form include skin lotions, creams, emulsions, gels, aerosols, ointments, and patches. Agents, paste agents, plaster agents, essences, packs, cleaning agents, bath preparations, foundations, powders, lipsticks and the like.
[0009]
The compounding amount of the extract of pine cone used in the present invention is 0.0001% by weight or more, preferably 0.001 to 10% by weight in terms of the dry solid in the total amount of the external preparation for skin of the present invention. If it is less than 0.001% by weight, a sufficient effect cannot be expected. When it exceeds 10% by weight, the effect is not enhanced and it is uneconomical. In addition, the addition method may be added in advance or during the production, and may be appropriately selected in consideration of workability.
[0010]
【Example】
EXAMPLES Next, although an Example is given and this invention is demonstrated in detail, this invention is not limited to this. In addition, the part of the compounding amount shown in the Examples means part by weight, and% means% by weight.
[0011]
Manufacture example 1 Juniper hot water extract 1000 ml of water is added to 50 g of a mixture of Juniper stalk and leaves, extracted at 95-100 ° C. for 2 hours, filtered, and the filtrate is concentrated to dryness. 10.5 g of extract was obtained.
[0012]
Production Example 2 Juniper ethanol extract 1000 ml of ethanol was added to 50 g of mushroom leaves, extracted at room temperature for 7 days, filtered, and the filtrate was concentrated and dried to obtain 4.0 g of Juniper ethanol extract.
[0013]
Production Example 3 Juniper 1,3-Butylene Glycol Extract To 1000 g of 1,3-butylene glycol was added to 50 g of dried pine pine herb, extracted for 10 days at room temperature, filtered, and Jematsu 1,3-butylene glycol 800 g of extract was obtained.
[0014]
Example 1 lotion formula
1. Kashimatsu hot water extract (Production Example 1) 0.1 part
2. 1,3-Butylene glycol 8.0
3. Glycerin 2.0
4. Xanthan gum 0.02
5. Citric acid 0.01
6. Sodium citrate 0.1
7. Ethanol 5.0
8. Methyl paraoxybenzoate 0.1
9. Polyoxyethylene hydrogenated castor oil (40E.O.) 0.1
10. Perfume appropriate amount
11. Make the total amount to 100 with purified water [Production method] Components 1 to 6, 11 and 7 to 10 are uniformly dissolved, mixed and filtered to obtain a product.
[0015]
Comparative Example 1 Conventional lotion In Example 1 of the conventional lotion, the hot spring water extract was replaced with purified water.
[0016]
Example 2 Cream formulation
1. Junimatsu ethanol extract (Production Example 2) 0.05 part
2. Squalane 5.5
3. Olive oil 3.0
4. Stearic acid 2.0
5. Beeswax 2.0
6. Octyldodecyl myristate 3.5
7. Polyoxyethylene cetyl ether (20E.O.) 3.0
8. Behenyl alcohol 1.5
9. Glycerol monostearate 2.5
10. 1,3-Butylene glycol 8.5
11. Methyl paraoxybenzoate 0.2
12. Ethyl paraoxybenzoate 0.05
13. Fragrance 0.1
14. Make the total amount to 100 with purified water [Production method] Components 2 to 9 are dissolved by heating and mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 1, 10-12, and 14 are heated and dissolved and mixed, and kept at 75 ° C. to form an aqueous phase. Add the aqueous phase to the oil phase, emulsify, cool with stirring, add component 13 at 45 ° C, and cool to 30 ° C to make the product.
[0017]
Example 3 Emulsion formulation
1. Kashimatsu 1,3-butylene glycol extract (Production Example 3) 1.0 part
2. Squalane 5.0
3. Olive oil 5.0
4. Jojoba oil 5.0
5. Cetanol 1.5
6. Glycerol monostearate 2.0
7. Polyoxyethylene cetyl ether (20E.O.) 3.0
8. Polyoxyethylene sorbitan monooleate (20E.O.) 2.0
9. Propylene glycol 1.0
10. Glycerin 2.0
11. Methyl paraoxybenzoate 0.2
12. Fragrance 0.1
13. Make the total amount to 100 with purified water [Production Method] Components 2 to 8 are dissolved by heating and mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 1, 9-11, and 13 are heated and dissolved and mixed, and kept at 75 ° C. to form an aqueous phase. Add the aqueous phase to the oil phase, emulsify, cool with stirring, add component 12 at 45 ° C, and cool to 30 ° C to make the product.
[0018]
Comparative Example 2 Conventional Emulsion In Example 3, the conventional emulsion was prepared by replacing the Kamamatsu 1,3-butylene glycol extract with 1,3-butylene glycol.
[0019]
Example 4 Gel formulation formulation
1. Kashimatsu 1,3-butylene glycol extract (Production Example 3) 5.0 parts
2. Ethanol 5.0
3. Methyl paraoxybenzoate 0.1
4. Polyoxyethylene hydrogenated castor oil (60E.O.) 0.1
5. Perfume appropriate amount
6. 1,3-Butylene glycol 5.0
7. Glycerin 5.0
8. Xanthan gum 0.1
9. Carboxyvinyl polymer 0.2
10. Potassium hydroxide 0.2
11. Make the total amount 100 with purified water [Manufacturing method] Components 2 to 5 and components 1 and 6 to 11 are uniformly dissolved, mixed and filtered to obtain a product.
[0020]
Example 5 Ointment Formulation Amount
1. Kashimatsu hot water extract (Production Example 1) 1.0 part
2. Polyoxyethylene cetyl ether (30E.O.) 2.0
3. Glycerol monostearate 10.0
4. Liquid paraffin 5.0
5. Cetanol 6.0
6. Methyl paraoxybenzoate 0.1
7. Propylene glycol 10.0
8. Make the total amount to 100 with purified water [Production Method] Components 2 to 5 are heated and dissolved and mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 1 and 6 to 8 are dissolved by heating and mixed, and kept at 75 ° C to form an aqueous phase. Add the water phase to the oil phase, emulsify, and cool to 30 ° C with stirring to make the product.
[0021]
Example 6 Pack formulation
1. Hamamatsu Hot Water Extract (Production Example 1) 0.5 part
2. Polyvinyl alcohol 12.0
3. Ethanol 5.0
4. 1,3-Butylene glycol 8.0
5. Methyl paraoxybenzoate 0.2
6. Polyoxyethylene hydrogenated castor oil (20E.O.) 0.5
7. Citric acid 0.1
8. Sodium citrate 0.3
9. Perfume appropriate amount
10. Make the total amount to 100 with purified water. [Production method] Dissolve components 1 to 10 uniformly to make a product.
[0022]
Example 7 Foundation formulation
1. Kashimatsu 1,3-butylene glycol extract (Production Example 3) 1.0 part
2. Stearic acid 2.4
3. Polyoxyethylene sorbitan monostearate (20E.O.) 1.0
4. Polyoxyethylene cetyl ether (20E.O.) 2.0
5. Cetanol 1.0
6. Liquid lanolin 2.0
7. Liquid paraffin 3.0
8. Isopropyl myristate 6.5
9. Butyl paraoxybenzoate 0.1
10. Carboxymethylcellulose sodium 0.1
11. Bentonite 0.5
12. Propylene glycol 4.0
13. Triethanolamine 1.1
14. Methyl paraoxybenzoate 0.2
15. Titanium dioxide 8.0
16. Talc 4.0
17. Bengala 5.0
18. Perfume appropriate amount
19. Make the total amount 100 with purified water [Manufacturing method] Add component 10 well swelled with component 10 and dissolve component 13 in the remaining component 19, then components 1, 11 Add ~ 14 and mix uniformly to make the aqueous phase. Ingredients 2-9 are dissolved by heating and kept at 80 ° C. to form an oil phase. Ingredients 15 to 17 are pulverized with a pulverizer, added to the aqueous phase, stirred with a homomixer and kept at 75 ° C. Add oil phase to this water phase with stirring, cool, add component 18 at 45 ° C, cool to 30 ° C with stirring to make the product.
[0023]
Example 8 Hair cream formulation
1. Stearic acid 2.0 parts
2. Stearyl alcohol 2.0
3. Liquid paraffin 8.0
4. Glycerol monostearate 2.3
5. Sorbitan monooleate 2.5
6. Polyoxyethylene sorbitan monooleate (10E.O.) 0.8
7. Juniper 1,3-butylene glycol extract (Production Example 3) 0.2
8. Glycerin 6.0
9. Methyl paraoxybenzoate 0.1
10. Perfume appropriate amount
11. Make the total amount to 100 with purified water [Production method] Components 1 to 6 are dissolved by heating and mixed, and kept at 70 ° C to form an oil phase. Ingredients 7 to 10 are heated and dissolved and mixed, and kept at 75 ° C. to form an aqueous phase. Add the water phase to the oil phase, emulsify, cool with stirring, add component 10 at 45 ° C, and cool to 30 ° C to make the product.
[0024]
Example 9 Formulation for bath preparation
1. Sodium bicarbonate 50.0 parts
2. Kashimatsu hot water extract (Production Example 1) 0.5
3. Yellow 202 No.
4. Perfume appropriate amount
5. Make the total amount 100 with sodium sulfate. [Production method] Ingredients 1 to 5 are uniformly mixed to make a product.
[0025]
【The invention's effect】
The pine extract of the present invention has an excellent histamine release inhibitory action (anti-inflammatory action), and the skin external preparation characterized by containing the pine extract has an excellent skin beautifying action.
Next, experimental examples will be given to explain the effects of the present invention in detail.
[0026]
Experimental Example 1 Action to suppress histamine release (anti-inflammatory action)
Histamine release inhibitory action was measured using mast cells collected from the abdominal cavity of male Spraque-Dawley rats. That is, the effect of inhibiting histamine release from mast cells by 1 μg / ml compound 48/80 was determined as the release inhibition rate. Mast cells were collected by the method of Sullivan et al. (J. Immunology, 114 (5), 1473, 1975), and histamine was quantified by the method of May et al. (J. Allergy, 46, 12-20, 1970). The results of the experiment are shown in Table 1. As a result, the pine extract showed an excellent inhibitory effect on histamine release. The sample used was a freeze-dried product of the extracts of Production Examples 1 and 2, and an evaporation residue of the extract of Production Example 3.
[0027]
[Table 1]
[0028]
Experimental Example 2 Skin beautification 15 women (21 to 46 years old) who suffer from rough skin using the lotion of Example 1, the emulsion of Example 3, the conventional lotion of Comparative Example 1 and the conventional emulsion of Comparative Example 2. A one-month use test was conducted on the subjects. After use, the improvement effect of rough skin was judged by a questionnaire. The results are shown in Table 2. As a result, the external preparation for skin characterized by containing an extract of pine cones showed an excellent skin beautifying action.
[0029]
[Table 2]
[0030]
The use test was similarly applied to the cream of Example 2, the gel of Example 4, the ointment of Example 5, the pack of Example 6, the foundation of Example 7, the hair cream of Example 8, and the bath preparation of Example 9. As a result, it showed an excellent skin effect.
As described above, the pine extract of the present invention has an excellent inhibitory effect on the release of histamine, and the external preparation for skin characterized by containing the extract exhibits an excellent skin beautifying effect. It was.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP36458397A JP3799151B2 (en) | 1997-12-17 | 1997-12-17 | Topical skin preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP36458397A JP3799151B2 (en) | 1997-12-17 | 1997-12-17 | Topical skin preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH11180881A JPH11180881A (en) | 1999-07-06 |
| JP3799151B2 true JP3799151B2 (en) | 2006-07-19 |
Family
ID=18482171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP36458397A Expired - Fee Related JP3799151B2 (en) | 1997-12-17 | 1997-12-17 | Topical skin preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3799151B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2864446B1 (en) * | 2003-12-29 | 2006-03-03 | Secma Biotechnologies Marines | USE IN A COSMETIC OR PHARMACEUTICAL COMPOSITION OF AT LEAST ONE LYIPHILISATE OF DIFFERENTIATED VEGETABLE CELLS FOR DEPIGMENTING AND / OR LIGHTENING, PROTECTING AND REGENERATING EPIDERMA |
-
1997
- 1997-12-17 JP JP36458397A patent/JP3799151B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH11180881A (en) | 1999-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009029734A (en) | External preparation for skin | |
| JP2002370922A (en) | Cosmetics containing plum extract | |
| JP4033981B2 (en) | Testosterone 5α-reductase inhibitor | |
| JP4866501B2 (en) | Topical skin preparation | |
| JP2003095858A (en) | Skin care preparation | |
| JP2001187742A (en) | Testosterone-5α-reductase inhibitor | |
| JP2896815B2 (en) | Cosmetics | |
| JP4628604B2 (en) | Skin preparation | |
| JP5154835B2 (en) | Whitening cosmetics | |
| JP3799151B2 (en) | Topical skin preparation | |
| JPH1017456A (en) | Cell-activating agent, cosmetic and hair-growing agent | |
| JP2000159653A (en) | Preparation for external use for skin | |
| JPH0570338A (en) | Cosmetic | |
| JP2011219462A (en) | Cosmetic or phamaceutical composition containing kuzu flower extract | |
| JP4224387B2 (en) | Topical skin preparation | |
| JP3156224B2 (en) | Anti-inflammatory agent | |
| JP3452671B2 (en) | External preparation for skin | |
| JP4457133B2 (en) | External preparation for skin and whitening agent | |
| JP2003026594A (en) | Hair tonic | |
| JP4607267B2 (en) | Photoimmune suppression improver | |
| JP4473439B2 (en) | Whitening agent | |
| JP5666344B2 (en) | Hair restorer | |
| JP4037836B2 (en) | Hyaluronidase activity inhibitor | |
| JPH11199464A (en) | External preparation for skin | |
| JP3499387B2 (en) | External preparation for skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20041116 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041203 |
|
| TRDD | Decision of grant or rejection written | ||
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20060327 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060411 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060424 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120428 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130428 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140428 Year of fee payment: 8 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |